1. Home
  2. UBCP vs IMMX Comparison

UBCP vs IMMX Comparison

Compare UBCP & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UBCP

United Bancorp Inc.

HOLD

Current Price

$14.16

Market Cap

77.4M

Sector

Finance

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$6.47

Market Cap

82.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UBCP
IMMX
Founded
1902
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.4M
82.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
UBCP
IMMX
Price
$14.16
$6.47
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
7.0K
1.3M
Earning Date
11-06-2025
11-07-2025
Dividend Yield
6.67%
N/A
EPS Growth
N/A
N/A
EPS
1.31
N/A
Revenue
$30,516,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.59
N/A
P/E Ratio
$10.58
N/A
Revenue Growth
4.40
N/A
52 Week Low
$12.25
$1.34
52 Week High
$15.64
$7.73

Technical Indicators

Market Signals
Indicator
UBCP
IMMX
Relative Strength Index (RSI) 63.45 66.71
Support Level $13.21 $4.50
Resistance Level $14.30 $7.73
Average True Range (ATR) 0.37 0.68
MACD 0.07 0.20
Stochastic Oscillator 74.16 65.44

Price Performance

Historical Comparison
UBCP
IMMX

About UBCP United Bancorp Inc.

United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: